Equities

Bioquest Corp

BQST:PKC

Bioquest Corp

Actions
  • Price (USD)0.0227
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 07 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioquest Corp. is primarily focused on acquiring companies in the green energy sector. The Company has executed a letter of intent to acquire all of the issued and outstanding shares of Progressus Clean Technologies, Inc. (Progressus), which is a private company. Progressus is a venture stage green technology company focused on the development of hydrogen generation and separation technologies. Progressus owns the rights to intellectual property that enables the extraction of dilute amounts of hydrogen at purity from a various gas stream. The Company has not generated any revenue.

  • Revenue in USD (TTM)0.00
  • Net income in USD-507.41k
  • Incorporated2011
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Black Bird Biotech Inc36.33k-836.14k98.40k4.00------2.71-0.0018-0.00180.00005-0.00050.27180.317813.319,082.50-625.64-433.36----27.55---2,301.51-1,800.060.0154-0.6032-----20.96--8.42------
Pure Harvest Corporate Group Inc2.48m-6.67m157.19k25.00--0.1035--0.0635-0.0901-0.09010.03830.02010.26441.4640.6499,070.40-70.96---136.76--33.83---268.37--0.5886-0.8660.7639--1,808.41---459.26------
Gelstat Corp1.68m-1.22m157.50k2.00--0.0215--0.0937-0.0033-0.00330.00460.0140.30214.17--840,285.00-21.96---26.29--28.99---72.69--0.3216-134.790.0267---66.81---60.17------
Bioquest Corp0.00-507.41k260.72k-----------0.0485-0.04850.00-0.04670.00-------3,483.76-----------------3.88--------64.67------
DMK Pharmaceuticals Corp3.62m-21.16m303.06k11.00------0.0837-8.69-9.181.04-0.49180.34325.665.54329,062.70-200.59-79.00---113.05-37.304.85-584.50-347.590.5355------115.34-18.3124.28---20.10--
Life Stem Genetics Inc0.00-568.02k393.34k1.00--0.21-----0.013-0.0130.000.00760.00----0.00-198.83---330.32--------------0.0241--------------
Scisparc Ltd0.00-6.96m532.75k3.00--21.87-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
ITonis Inc0.00-1.17m533.19k-----------0.0012-0.00120.00-0.00040.00-------187.63---1,169.36-------------0.8999---------506.86------
Evofem Biosciences Inc16.01m47.49m595.78k37.000.001--0.01250.0372-5.92-5.920.0826-1.360.9351.722.73432,756.80295.02-211.64----63.65--315.54-1,031.550.0757-2.91----8.20--164.08---10.59--
Neutra Corp17.40k-474.98k729.47k--------41.92-0.0002-0.00020.00001-0.00030.27860.4126-----758.75-682.94----46.15---2,723.22-2,758.850.0009-14.06-----26.09--22.28------
Data as of May 07 2024. Currency figures normalised to Bioquest Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.